Evidence map›Paper›PMID 41924527›Full record

ArticleFrontiers in endocrinology2026

Insulin-stimulated glucose uptake is impaired in senescent human adipocytes.

Ida Alexandersson, Henrik Palmgren, Martin Uhrbom, Jan Oscarsson, Jeremie Boucher

Abstract read
In one paragraph

Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ida AlexanderssonBioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Henrik PalmgrenBioscience Renal, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Martin UhrbomAssays, Profiling & Cell Sciences (APCS), Discovery Sciences, AstraZeneca, Gothenburg, Sweden.
Jan OscarssonBiopharmaceuticals R&D, Late-Stage Clinical Development, Cardiovascular, Renal and Metabolism, AstraZeneca, Gothenburg, Sweden.
Jeremie BoucherDepartment of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cell senescence, a state of cell cycle arrest induced by intrinsic or extrinsic stress, is linked to aging and aging-associated diseases. Senescence markers are elevated in adipose tissue with age and in obesity. Recently, it was shown that human mature adipocytes can undergo senescence in response to hyperinsulinemia. However, the functional consequences of adipocyte cell senescence remain poorly understood. Methods: To study the impact of cellular senescence on human adipocyte function, we induced senescence in differentiated primary human preadipocytes (referred to as human adipocytes) using nutlin-3a, doxorubicin and etoposide. Expression of senescence markers, insulin receptor signaling, response to lipolytic stimuli and insulin mediated glucose uptake were investigated. Results: The senescence-inducing compounds increased expression of senescence markers p21, p53, activity of senescence-associated β-galactosidase (SA-βgal) and secretion of senescence-associated secreted factors (SASP). We showed that insulin-stimulated glucose uptake, but not basal glucose uptake, was significantly reduced in senescent adipocytes. Insulin receptor signaling was largely unaffected, while expression of insulin receptor signaling proteins and especially GLUT4 expression were reduced. Expression of some adipocyte marker genes, including Conclusions: Our findings indicate that cellular senescence impairs insulin-stimulated glucose uptake but not lipolytic capacity; changes that may contribute to impaired glucose control and ectopic fat accumulation.

Indexed as

AdipocytesCellular SenescenceGlucoseInsulinAdiponectinCells, CulturedGlucose Transporter Type 4HumansLipaseLipolysisReceptor, InsulinSignal TransductionAdiponectinGlucoseGlucose Transporter Type 4InsulinLipaseReceptor, InsulinSLC2A4 protein, humanadipocytescellular senescenceglucose uptakeinsulin sensitivitylipolysis

Identifiers

PMID41924527
PMCPMC13035520

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.